• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail

Millennium Dental Technologies Inc. 07-Jun-05

Department of Health and Human Services' logoDepartment of Health and Human Services

Public Health Service
Food and Drug Administration


Los Angeles District
19701 Fairchild
Irvine, California 92612-2506
Telephone (949) 608-2900




June 7, 2005

W/L 16-05

Robert H. Gregg II
Millennium Dental Technologies Inc.
10945 South St., Ste 104-A
Cerritos, CA 90703

Dear Dr. Gregg:

Your firm manufactures medical devices. During an inspection of your manufacturing facility located in Cerritos, California, conducted between March 15 and April 12, 2005, our investigator found significant deviations from the Current Quality System Regulation (QSR) for finished devices (Title 21, Code of Federal Regulations, Part 820). Such deviations cause human devices manufactured at this facility to be adulterated within the meaning of Section 501(h) of the Federal Food, Drug and Cosmetic Act (henceforth the "Act").

Section 501 (h) of the Act states that a device shall be deemed adulterated if the methods used in, or the facilities or controls used for its manufacture, packing, storage, or installation do not conform to or are not administered in conformity with current Quality System Regulations, to assure that such device will be safe and effective.

Our inspection found the following device QSR deficiencies:

1. Not all complaints you have received have been reviewed and evaluated to determine whether an investigation is necessary. Specifically, you have received 19 complaints which were reviewed during the inspection that have no documentation concerning whether or not an investigation is/was needed. Additionally, you do not have documentation of an investigation to determine the root cause for any of your complaints. [21 CFR 820.198(a)]

2. You have not identified and/or analyzed all quality data to identify existing and/or potential causes of nonconforming product or other quality problems. Specifically, you have complaint and returned merchandise (RMA) data lacking documentation of any investigation. [21 CFR 820.100(a)(1)]

3. You have not documented corrective and/or preventive action needed to prevent the recurrence of nonconforming product or other quality issues. Specifically, you have no documentation to support any corrective and/or preventive action to address nonconforming or other quality issues . [21 CFR 820.100(b)]

4. Your quality audit procedure is incomplete. Specifically, you have riot performed any quality audits. [21 CFR 820.22]

5. You have not documented acceptance activities. Specifically, you do not have a qualified vendor list nor have you performed any vendor audits . [21 CFR 820.50]

6. Software used as part of the quality system has not been validated for its intended use according to an established protocol . Specifically, you are using a software system for your procedures that allows procedures to have inconsistent effective, approved and release dates. [21 CFR 820.70(i)]

The above is not intended to be an all-inclusive list of violations . As a manufacturer of human medical devices, you are responsible for assuring that your overall operations and the products you manufacture and distribute are in compliance with the law. You should take prompt action to correct these violations and to establish procedures to prevent their recurrence. Failure to promptly correct these violations may result in regulatory action without further notice, such as seizure and/or injunction. Other Federal Agencies are informed about the Warning Letters issued so they may consider this information when awarding government contracts for medical device products.

We are in receipt of your May 10, 2005 response to the Form FDA-483, Inspectional Observations, issued to you at the close of the most recent inspection. While your response commits to correction of your documentation, your response is silent as to any corrective action planned to address the lack of a thorough investigation of complaints and RMAs to determine if additional product may be adulterated and/or if a root cause of quality shortcomings can be identified. Additionally, your response does not clearly detail nor provide supporting documentation of corrections. While written procedures are required, it is of far greater importance that appropriate action be taken with respect to any and all potential quality issues. You should provide written commitment of your planned actions with respect to investigation of RMAs, complaints and other potential quality concern data sources.

You should notify this office in writing within fifteen (15) working days of receipt of this letter, of the specific steps you have taken to correct the noted violations, including an explanation of each step being taken to prevent the recurrence of similar violations. If corrective action cannot be completed within fifteen (15) working days, state the reason for the delay and the time within which the corrections will be completed. Also include copies of any available documentation demonstrating that corrections have been made. If you have any questions or need clarification regarding this letter prior to your written response, you may contact Barbara Rincon, Compliance Officer at telephone number (949) 608-4439.

Your reply should be directed to:

Pamela B. Schweikert
Director, Compliance Branch
U.S. Food & Drug Administration
19701 Fairchild
Irvine, CA 92612



Alonza E. Cruse
District Director